公开(公告)号：US20190030010A1

公开(公告)日：2019-01-31

申请号：US16148647

申请日：2018-10-01

申请人： ONO PHARMACEUTICAL CO., LTD.

发明人： Atsushi NAGANAWA ,  Kensuke KUSUMI ,  Kazuhiro OTSUKI ,  Tetsuya SEKIGUCHI ,  Akito KAKUUCHI ,  Koji SHINOZAKI ,  Hiroshi YAMAMOTO ,  Shigeyuki NONAKA

IPC分类号： A61K31/445 ,  A61K31/397 ,  A61K31/4545 ,  A61K31/40 ,  A61K31/4523 ,  A61K31/453 ,  C07D211/52 ,  C07D207/16 ,  C07D207/12 ,  C07D205/04 ,  C07D401/12 ,  C07D211/48 ,  C07D405/12 ,  A61K31/454

摘要： The compound of the formula (I-1): wherein all the symbols have the same meanings as described in the specification, has two cyclic groups, particularly phenoxy groups at specific substitution positions and thus has high human S1P2 antagonistic activity. The compound may therefore be used as a therapeutic agent for S1P2-mediated diseases such as diseases resulting from vascular constriction, fibrosis, and respiratory diseases.

公开(公告)号：US20180042908A1

公开(公告)日：2018-02-15

申请号：US15784376

申请日：2017-10-16

申请人： ONO PHARMACEUTICAL CO., LTD.

发明人： Atsushi NAGANAWA ,  Kensuke KUSUMI ,  Kazuhiro OTSUKI ,  Tetsuya SEKIGUCHI ,  Akito KAKUUCHI ,  Koji SHINOZAKI ,  Hiroshi YAMAMOTO ,  Shigeyuki NONAKA

IPC分类号： A61K31/445 ,  A61K31/454 ,  A61K31/453 ,  A61K31/4523 ,  A61K31/40 ,  A61K31/397 ,  C07D401/12 ,  C07D207/12 ,  C07D211/52 ,  C07D207/16 ,  C07D211/48 ,  C07D205/04 ,  A61K31/4545 ,  C07D405/12

CPC分类号： A61K31/445 ,  A61K31/397 ,  A61K31/40 ,  A61K31/4523 ,  A61K31/453 ,  A61K31/454 ,  A61K31/4545 ,  C07D205/04 ,  C07D207/12 ,  C07D207/16 ,  C07D211/48 ,  C07D211/52 ,  C07D401/12 ,  C07D405/12

摘要： The compound of the formula (I-1): wherein all the symbols have the same meanings as described in the specification, has two cyclic groups, particularly phenoxy groups at specific substitution positions and thus has high human S1P2 antagonistic activity. The compound may therefore be used as a therapeutic agent for S1P2-mediated diseases such as diseases resulting from vascular constriction, fibrosis, and respiratory diseases.

公开(公告)号：US20160213660A1

公开(公告)日：2016-07-28

申请号：US15089690

申请日：2016-04-04

申请人： ONO PHARMACEUTICAL CO., LTD.

发明人： Atsushi NAGANAWA ,  Kensuke KUSUMI ,  Kazuhiro OTSUKI ,  Tetsuya SEKIGUCHI ,  Akito KAKUUCHI ,  Koji SHINOZAKI ,  Hiroshi YAMAMOTO ,  Shigeyuki NONAKA

IPC分类号： A61K31/445 ,  A61K31/453 ,  A61K31/40 ,  A61K31/454 ,  A61K31/397 ,  A61K31/4545 ,  A61K31/4523

CPC分类号： A61K31/445 ,  A61K31/397 ,  A61K31/40 ,  A61K31/4523 ,  A61K31/453 ,  A61K31/454 ,  A61K31/4545 ,  C07D205/04 ,  C07D207/12 ,  C07D207/16 ,  C07D211/48 ,  C07D211/52 ,  C07D401/12 ,  C07D405/12

摘要： The compound of the formula (I-1): wherein all the symbols have the same meanings as described in the specification, has two cyclic groups, particularly phenoxy groups at specific substitution positions and thus has high human S1P2 antagonistic activity. The compound may therefore be used as a therapeutic agent for S1P2-mediated diseases such as diseases resulting from vascular constriction, fibrosis, and respiratory diseases.

摘要翻译： 式（I-1）的化合物：其中所有符号具有与说明书中所述相同的含义，具有两个环状基团，特别是特定取代位置的苯氧基，因此具有高的人S1P2拮抗活性。 因此，该化合物可用作S1P2介导的疾病如血管收缩，纤维化和呼吸系统疾病引起的疾病的治疗剂。

公开(公告)号：US20160039757A1

公开(公告)日：2016-02-11

申请号：US14780152

申请日：2014-03-25

申请人： ONO PHARMACEUTICAL CO., LTD.

发明人： Kensuke KUSUMI ,  Atsushi NAGANAWA ,  Kazuhiro OTSUKI ,  Tetsuya SEKIGUCHI ,  Koji SHINOZAKI ,  Hiroshi YAMAMOTO ,  Yasuko YAMAMOTO

IPC分类号： C07D211/52 ,  C07D207/12

CPC分类号： C07D211/52 ,  C07D207/12 ,  C07D211/44 ,  C07D211/48

摘要： An object of the present invention is to provide a compound having strong human S1P2 antagonistic activity in order to develop a useful medicament for therapy of a S1P2-mediated disease such as a disease resulting from vascular constriction, fibrosis and respiratory disease. The compound represented by the general formula (I), wherein all the symbols have the same meanings as described in the specification, has a halogen atom or a haloalkyl group and a phenoxy group at certain substitution sites, and thus has strong human S1P2 antagonistic activity. Therefore, the compound can be a therapeutic agent for a S1P2-mediated disease, such as a disease resulting from vascular constriction, fibrosis and respiratory disease.

摘要翻译： 本发明的目的是提供具有强人S1P2拮抗活性的化合物，以便开发用于治疗S1P2介导的疾病如由血管收缩，纤维化和呼吸系统疾病引起的疾病的有用药物。 由通式（I）表示的化合物，其中所有符号具有与说明书中所述相同的含义，在某些取代位置具有卤素原子或卤代烷基和苯氧基，因此具有强的人S1P2拮抗活性 。 因此，该化合物可以是S1P2介导的疾病的治疗剂，例如由血管收缩，纤维化和呼吸道疾病引起的疾病。

公开(公告)号：US20150126486A1

公开(公告)日：2015-05-07

申请号：US14592100

申请日：2015-01-08

申请人： ONO PHARMACEUTICAL CO., LTD.

发明人： Atsushi NAGANAWA ,  Kensuke KUSUMI ,  Kazuhiro OTSUKI ,  Tetsuya SEKIGUCHI ,  Akito KAKUUCHI ,  Koji SHINOZAKI ,  Hiroshi YAMAMOTO ,  Shigeyuki NONAKA

IPC分类号： C07D205/04 ,  C07D401/12 ,  C07D207/12 ,  C07D211/48

CPC分类号： A61K31/445 ,  A61K31/397 ,  A61K31/40 ,  A61K31/4523 ,  A61K31/453 ,  A61K31/454 ,  A61K31/4545 ,  C07D205/04 ,  C07D207/12 ,  C07D207/16 ,  C07D211/48 ,  C07D211/52 ,  C07D401/12 ,  C07D405/12

摘要： The compound represented by the formula (I-1): wherein all the symbols have the same meanings as described in the specification, has two cyclic groups, particularly phenoxy groups at specific substitution positions and thus has high human S1P2 antagonistic activity. The compound may therefore be used as a therapeutic agent for S1P2-mediated diseases such as diseases resulting from vascular constriction, fibrosis and respiratory diseases.

摘要翻译： 由式（I-1）表示的化合物：其中所有符号具有与说明书中所述相同的含义，具有两个环状基团，特别是在特定取代位置的苯氧基，因此具有高的人S1P2拮抗活性。 因此，该化合物可用作S1P2介导的疾病如血管收缩，纤维化和呼吸系统疾病引起的疾病的治疗剂。